How to Inject Bronchogen

The Terminology Confusion: "Injection" vs. Administration Routes

Bronchogen's marketing and community discussions often conflate "injection" with general peptide administration, causing confusion. In the broader peptide sphere, compounds like BPC-157, TB-500, and growth hormone-releasing peptides are commonly subcutaneously injected. Bronchogen, however, is not marketed as an injectable product in Russia or Europe. It exists primarily as oral capsules and sublingual powders. Peptide community forums sometimes discuss "injecting bronchogen," but this represents off-label use by individuals obtaining research-grade peptide powder and reconstituting it for SC injection—not standard clinical practice.

This article addresses actual delivery methods for commercially available and research-grade bronchogen, clarifying the absence of injection as a standard administration route.

Oral Capsules: The Standard Bronchogen Delivery

Revitacare (Russian brand, approved as a dietary supplement) and other bronchogen formulations are sold as oral capsules containing 50-100 mcg per capsule. The exact formulation and excipients vary by manufacturer—some use enteric coating to protect from gastric acid, others include absorption enhancers or stabilizing compounds. Typical dosing: one 100 mcg capsule daily, taken with water, on an empty stomach (1 hour before meals or 2 hours after).

Advantage: Oral capsules require no specialized technique or sterility concerns, making them suitable for self-administration and long-term use. Disadvantage: oral bioavailability of peptides is inherently poor (<5% for most free peptides), and exact absorption from bronchogen capsules is unknown. Users report variable response rates (some effective, others report no effect).

Sublingual Administration: The Preferred Alternative

Sublingual delivery—placing bronchogen powder under the tongue—exploits the rich vascularization and thin epithelium of sublingual mucosa. Users purchase bronchogen powder (100-500 mcg per serving) and place it sublingually for 5-10 minutes, allowing absorption through mucosal tissue. The peptide reaches bloodstream and eventually bronchial tissue within 30 minutes to 2 hours.

Practical sublingual protocol: (1) Measure 100-200 mcg of bronchogen powder, (2) Place under tongue, (3) Keep mouth closed and avoid swallowing for 5-10 minutes, (4) Swallow remaining residue. Some users mix powder with a small amount of water to aid absorption. Dosing frequency: once daily, typically in morning.

Advantages: Bypasses gastric acid (eliminating degradation risk), achieves likely-higher bioavailability than oral capsules, produces faster onset (30min-2hr versus 2-4 hr for oral). Disadvantages: requires careful measurement of powder dosing, sublingual irritation possible (rare), less convenient than capsule dosing.

Sublingual Powder Sourcing and Quality Control

Bronchogen powder is obtained from research chemical suppliers in Russia or Europe, not from pharmaceutical manufacturers (due to lack of FDA approval in US/Canada). Quality control is a concern: peptide powder can degrade if exposed to heat, light, or moisture. Reliable suppliers store powder in desiccated, nitrogen-flushed containers. Upon receipt, users should store bronchogen powder in a freezer (-20°C) or refrigerator (4°C) to maximize stability.

Before use, inspect powder for discoloration or clumping (signs of degradation). Measure doses carefully using a precision milligram scale (±0.5 mg accuracy, available for <$20 online). Guessing at "a small pinch" will result in highly variable doses (25-500 mcg), defeating consistency.

Subcutaneous Injection: Research Use Only

SC injection of bronchogen is not standard but is used in some Russian clinical research protocols. Administration: bronchogen powder is reconstituted in sterile saline (0.9% sodium chloride) at 1000 mcg/mL concentration, creating a solution (volume depends on dose desired). Typical SC injection: 100-200 mcg (0.1-0.2 mL) administered SC into the abdomen, thigh, or upper arm, similar to insulin injection technique.

Requirements: (1) Sterile injection supplies (syringes, needles, alcohol wipes), (2) Aseptic technique to prevent infection, (3) Biological safety cabinet or clean environment, (4) Medical knowledge to select appropriate injection sites and avoid nerves/blood vessels. The infection risk with improper SC technique is substantial (localized abscess, systemic sepsis), making SC injection suitable only for individuals with medical training or direct medical supervision.

Advantages of SC injection: 100% bioavailability, rapid onset, sustained tissue depot (some users report more durable effects than sublingual). Disadvantages: infection risk, injection site reactions (pain, inflammation), requirement for sterile supplies and technique, regulatory legal issues (self-injection of research compounds).

Intranasal Administration: Theoretical But Not Established

Some peptide forums discuss intranasal (IN) bronchogen administration—spraying bronchogen powder or solution into nasal passages to reach nasal mucosa and lower respiratory tract via drainage. Theoretically, IN delivery could provide direct mucosal access to the respiratory epithelium. However, this is purely speculative; no published bronchogen IN studies exist, no commercial IN formulations are marketed, and the bioavailability, efficacy, and safety are completely unknown.

Intranasal peptides require excipient optimization (mucoadhesive compounds, pH buffering, permeation enhancers) to achieve adequate mucosal absorption. Standard bronchogen powder sprayed INTO the nose would likely result in rapid mucociliary clearance with minimal absorption. Until pharmaceutical optimization is done, IN administration is not recommended.

Inhalation (Aerosol): Why It Isn't Practical for Bronchogen

Inhalation therapy (using an inhaler or nebulizer to deliver particles directly to lungs) is ideal for respiratory drugs. Bronchodilators, corticosteroids, and some antibiotics use this route. Theoretically, bronchogen inhaled directly to bronchial tissue would achieve maximal local concentration with minimal systemic exposure. However, peptide aerosol formulation is technically difficult: peptides aggregate and precipitate in aqueous solutions, making nebulization problematic. Dry powder inhalers (DPIs) for peptides exist (e.g., human insulin via DPI) but require pharmaceutical engineering, particle engineering, and stability testing.

No commercial bronchogen aerosol product exists, and creating one would require substantial pharmaceutical development. Until such a product is developed and tested, inhalation is not an option.

Reconstitution and Stability Considerations

If using research-grade bronchogen powder, reconstitution may be necessary for injection or other routes. Reconstitution protocol: (1) Draw 0.5-1 mL of sterile saline into a syringe, (2) Inject into a vial containing bronchogen powder, (3) Gently swirl (do NOT shake) to dissolve, (4) Allow 5-10 minutes for complete dissolution. Avoid vigorous shaking, which creates air bubbles and increases peptide oxidation.

Stability of reconstituted bronchogen: room temperature (25°C), short-term stability is 24-48 hours (before bacterial overgrowth or peptide degradation). Refrigerated (4°C), stability extends to 1-2 weeks. Frozen (-20°C), reconstituted solution remains stable for months, though freeze-thaw cycles may reduce efficacy. For repeated dosing, reconstitute fresh every 3-5 days or store single-dose aliquots frozen.

Practical Recommendation: Sublingual vs. Oral vs. Parenteral

For users prioritizing convenience and safety, sublingual powder is the best compromise: no injection risk, higher likely bioavailability than oral capsules, faster onset, and achievable with basic equipment (precision scale, measuring spoon). For users unable to obtain powder, oral capsules are widely available and safe, despite uncertain bioavailability. SC injection is reserved for individuals with medical training, willing to accept infection risks, and seeking maximal dose certainty.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).